Physician profile
David A Olson
NPI 1598829830
$1,865.22
in general payments reported to CMS, 2019-2025
27 companies · $712 in 2025
The $712 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.12 · 2020: $12.19 · 2021: $92.75 · 2022: $428 · 2023: $268 · 2024: $339 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,272 · Education: $46.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,272.43 |
| Education | $46.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $311.59 | 2021-2025 | |
| Csl Behring | $180.47 | 2023-2025 | Hizentra |
| Pfizer INC. | $147.12 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $140.99 | 2022 | |
| Ucb, INC. | $123.72 | 2022-2024 | Nayzilam |
| Lilly USA, LLC | $110.55 | 2022-2024 | Amyvid, Emgality |
| Tg Therapeutics, INC. | $106.73 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.02 | 2025 | Hyqvia |
| Grifols USA, LLC | $89.61 | 2022-2025 | Gamunex-C |
| Otsuka America Pharmaceutical, INC. | $71.96 | 2023-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $63.13 | 2022 | |
| Argenx US, INC. | $59.77 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Acadia Pharmaceuticals INC | $51.24 | 2025 | Nuplazid |
| Emd Serono, INC. | $40.32 | 2025 | |
| Amgen INC. | $37.56 | 2019-2025 | Uplizna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $34.61 | 2025 | Ponvory |
| Biogen, INC. | $29.91 | 2022-2024 | Vumerity |
| Lundbeck LLC | $24.64 | 2024 | Rexulti |
| Alexion Pharmaceuticals, INC. | $23.50 | 2024 | Ultomiris |
| Eisai INC. | $20.66 | 2023 | |
| Genentech USA, INC. | $17.63 | 2023 | Enspryng, Ocrevus |
| Genzyme Corporation | $17.14 | 2022 | |
| Horizon Therapeutics Plc | $17.14 | 2023 | Uplizna |
| Novartis Pharmaceuticals Corporation | $15.74 | 2021 | |
| Linus Health, INC. | $14.13 | 2023 | |
| Celgene Corporation | $13.15 | 2024 | Zeposia |
| Allergan, INC. | $12.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.